The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

(2010) Tao Xu et al.   BMC CANCER

Expression of Molecular Markers in the Tumor and Survival Prognosis in Osteosarcoma

(2010) I. V. Boulytcheva et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

(2010) Ping Zhan et al.   Journal of Thoracic Oncology

Survival in high-grade osteosarcoma: improvement over 21 years at a single institution

(2009) P. Picci et al.   ANNALS OF ONCOLOGY

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

(2009) S J Schoenleber et al.   BRITISH JOURNAL OF CANCER

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

(2009) Ayesha Abdeen et al.   CANCER

The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma

(2009) M. Kaya et al.   JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

(2009) Ymera Pignochino et al.   Molecular Cancer

VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma

(2009) Quan Zhou et al.   SURGICAL ONCOLOGY-OXFORD